Participatory Medicine and Diabetes Care: A Clinician and Patient Education Initiative
Provided by the Academy for Continued Healthcare Learning.
This activity is supported by an educational grant from Novo Nordisk, Inc.
Scroll to the Bottom of this Information to Begin this Course
Release date: August 16, 2016
Valid through: August 16, 2017
Specialty: Endocrinology, Primary Care, Internal Medicine, Family/General Practice, Nursing
Estimated Time to Complete Activity: 75 minutes
This activity is intended for primary care providers including MDs, DOs, NPs, and PAs. The patient education activity is intended for patients with diabetes and their caregivers.
Despite clinical practice recommendations to personalize diabetes management, clinical inertia persists and approximately one-half of people with type 2 diabetes do not achieve glycemic control. Late initiation of injectable therapies, which in some patients occurs only after many years of high glycemic burden, is one of the major contributors. Another variable contributing to these gaps in care may be incomplete understanding of newer developments in therapies, devices, and treatment consensus. This activity will provide clinically focused education on insulin and non-insulin injectable therapies, overcoming clinical inertia, and the importance of participatory medicine.
Upon completion of this activity, participants should be better able to:
- Apply strategies to overcome clinical inertia in the initiation of injectable therapies in patients with T2D
- Identify different combinations of therapies with safety and efficacy profiles for patients with T2D
- Develop strategies to enhance communication with patients and their caregivers
- Physicians — maximum of 1.25 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Anne Peters, MD (Chair)
Professor of Medicine
Director, USC Clinical Diabetes Program
Keck School of Medicine
University of Southern California
Los Angeles, CA
Linda M. Siminerio, RN, PhD, CDE
Professor of Medicine
Executive Director, University of Pittsburgh Diabetes Institute
Physician Continuing Medical Education
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. ACHL also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.
The following financial relationships have been provided:
- Sources of Funding Research: Janssen, Medtronic Foundation
- Advisory Board/Consulting Agreements: Abbott Diabetes Care, Becton Dickinson, Bigfoot Biomedical, Biodel, Boehringer Ingelheim, CVS/Caremark, Eli Lilly and Company, Astra-Zeneca, Intarcia, Janssen, Lexicon, Medtronic-Minimed, Merck, Novo Nordisk, Omada Health, OptumRx, Thermalin
- Nothing to disclose
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online webcast and complete the post-test and evaluation forms. To receive credit, 75% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use: Novel insulin formulations, GLP-1 receptor agonists, and combination regimens under investigation.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.